ANDA file for Solid Oral Anti Epileptic Drug
- Home
- ANDA file for Solid Oral Anti Epileptic Drug
At Theracentric Innovations, we are proud to announce the submission of Abbreviated New Drugs Applications (ANDAs) for two groundbreaking pharmaceutical products:
1. Anti Epileptic Drug (AED): Our dedicated team has been tirelessly working on the development of an Anti Epileptic Drug that aims to make a significant impact in the field of neurology. The ANDA filing represents a crucial step toward introducing an advanced therapeutic option for individuals affected by epilepsy. We prioritize safety, efficacy, and accessibility in our pursuit of enhancing the quality of life for those living with epilepsy.
- Liquid Antifungal Drug: In response to the growing need for effective antifungal solutions, Thercentric Innovations has submitted an ANDA for a Liquid Antifungal Drug. This product is designed to address various fungal infections, offering a convenient liquid formulation that ensures ease of administration. Our commitment to innovation and quality shines through in this endeavor, as we strive to provide healthcare professionals with a valuable tool in the fight against fungal infections.